TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.
作者信息
Sparano Joseph A, Gray Robert
机构信息
Joseph A. Sparano, MD, Montefiore Hospital and Medical Center, Bronx, NY; and Robert Gray, PhD, Dana-Farber Cancer Institute, Boston, MA.
出版信息
J Clin Oncol. 2019 Jul 20;37(21):1841-1842. doi: 10.1200/JCO.19.00828. Epub 2019 Jun 7.
Abstract
摘要
相似文献
1
TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.Tailorx：已解答的问题、汲取的经验教训及尚存的知识空白
J Clin Oncol. 2019 Jul 20;37(21):1841-1842. doi: 10.1200/JCO.19.00828. Epub 2019 Jun 7.
2
Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.TAILORx 对基于人群的乳腺癌患者化疗处方和 21 基因复发评分指导治疗费用的影响。
Cancer. 2022 Feb 15;128(4):665-674. doi: 10.1002/cncr.33982. Epub 2021 Dec 2.
3
Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.70 岁以上患者是否需要常规进行复发评分检测？TAILORx 后对国家癌症数据库的评估。
Ann Surg Oncol. 2019 Oct;26(10):3152-3158. doi: 10.1245/s10434-019-07553-y. Epub 2019 Jul 24.
4
Reply to J.A. Sparano et al.对J.A. 斯帕拉诺等人的回复
J Clin Oncol. 2019 Jul 20;37(21):1842. doi: 10.1200/JCO.19.01147. Epub 2019 Jun 7.
5
Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.TAILORx 实践改变潜力：2010 年至 2015 年国家癌症数据库的回顾性分析。
Ann Surg Oncol. 2019 Oct;26(10):3397-3408. doi: 10.1245/s10434-019-07650-y. Epub 2019 Aug 19.
6
Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.采用分类回归树（CART）分析，通过组织病理学和免疫组织化学标志物预测 Oncotype DX 和 TAILORx 风险类别。
Breast. 2013 Oct;22(5):879-86. doi: 10.1016/j.breast.2013.04.008. Epub 2013 May 2.
7
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.激素受体阳性、淋巴结阴性乳腺癌患者局部区域复发的种族和民族差异：TAILORx 随机临床试验的事后分析。
JAMA Surg. 2023 Jun 1;158(6):583-591. doi: 10.1001/jamasurg.2023.0297.
8
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.21 基因复发评分在 26 到 100 之间的早期乳腺癌患者接受辅助化疗加内分泌治疗的临床结局：TAILORx 随机临床试验的二次分析。
JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794.
9
[Ⅳ. Clinical Trials on OncotypeDX-TAILORx and JBCRG-TR003 Trial].[四、OncotypeDX-TAILORx和JBCRG-TR003试验的临床试验]
Gan To Kagaku Ryoho. 2022 Dec;49(12):1324-1327.
10
Assessing the Impact of TAILORx on Breast Cancer Management.评估 TAILORx 对乳腺癌管理的影响。
Oncology (Williston Park). 2020 Jun 10;34(6):224-226.
引用本文的文献
1
Development and Validation of Data-Driven Estimates of Recurrence Risk and Treatment Benefit in Early Breast Cancer.早期乳腺癌复发风险和治疗获益的数据驱动估计值的开发与验证
J Clin Oncol. 2025 Mar 10;43(8):899-902. doi: 10.1200/JCO-24-02452. Epub 2024 Dec 12.
2
Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients.早期乳腺癌患者的肿瘤免疫微环境分析与 21 基因复发检测的相关性研究。
Eur J Med Res. 2022 Dec 17;27(1):293. doi: 10.1186/s40001-022-00917-3.
3
Whole-Transcriptome Profiling on Small FFPE Samples: Which Sequencing Kit Should Be Used?小福尔马林固定石蜡包埋样本的全转录组分析：应使用哪种测序试剂盒？
Curr Issues Mol Biol. 2022 May 13;44(5):2186-2193. doi: 10.3390/cimb44050148.
4
Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables.使用病理、临床和影像学变量的非线性组合对早期乳腺癌的远处复发风险进行定量评估。
J Biophotonics. 2020 Oct;13(10):e201960235. doi: 10.1002/jbio.201960235. Epub 2020 Aug 3.
5
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.Oncotype DX 乳腺癌检测结果对临床实践的影响：英国的经验。
Breast Cancer Res Treat. 2020 Apr;180(3):809-817. doi: 10.1007/s10549-020-05578-6. Epub 2020 Mar 13.
本文引用的文献
1
Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.评估早期乳腺癌复发风险：整合临床与基因组风险
J Clin Oncol. 2019 Mar 20;37(9):689-692. doi: 10.1200/JCO.18.01412. Epub 2019 Feb 11.
2
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.21基因检测作为HER2阴性乳腺癌化疗获益的预测指标
NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018.
3
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.基于 21 基因表达检测的乳腺癌辅助化疗。
N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.
4
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.根据复发评分结果接受治疗的雌激素受体阳性、人表皮生长因子受体2阴性、淋巴结阳性乳腺癌患者的临床结局：来自一项大型前瞻性设计登记研究的证据
NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017.
5
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.降低临床高风险、基因组低风险 pN0 和 pN1 早期乳腺癌患者化疗使用率：来自前瞻性、随机、III 期德国西部研究组（WSG）PlanB 试验的五年数据。
Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29.
6
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.比较 21 基因复发评分检测和 Adjuvant! 在淋巴结阴性、ER 阳性乳腺癌患者中的预后和预测效用：来自 NSABP B-14 和 NSABP B-20 的结果。
Breast Cancer Res Treat. 2011 May;127(1):133-42. doi: 10.1007/s10549-010-1331-z. Epub 2011 Jan 11.
7
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.与经典临床病理特征相比，21基因检测在激素受体阳性可手术乳腺癌中的预后效用。
J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4.
8
Development of the 21-gene assay and its application in clinical practice and clinical trials.21基因检测法的发展及其在临床实践和临床试验中的应用。
J Clin Oncol. 2008 Feb 10;26(5):721-8. doi: 10.1200/JCO.2007.15.1068.
9
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌化疗和激素治疗对复发及15年生存率的影响：随机试验综述
Lancet. 2005;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0.
Zotero 插件